23 May 2024
An exciting milestone in our pursuit to make CAR T-cell therapy a standard of care in New Zealand, the Environmental Protection Authority NZ has approved use of chimeric antigen receptor (CAR) T-cells in our phase 2 clinical trial with BioOra.
As a trial of this kind had never been done before in New Zealand, our team has put significant time and effort into working with national regulatory bodies such as the EPA and MedSafe to navigate and establish the necessary regulatory pathways to bring CAR T-cell technology to New Zealand.
In doing so, we have opened doors for similar life-saving cell therapy trials to be undertaken here in the future - whether our own or others.
Related articles
Community partnerships: Zephyr Consulting empowering emerging scientific talent
18 November 2024
Read more
In Focus: CAR T-cell therapy, the battle of the blood cells
26 September 2024
Read more
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
23 July 2024
Read more
A revolution in cancer care is near; here’s what’s needed to make it happen
9 May 2024
Read more
Significant milestone reached in first NZ CAR T-cell trial as preparations made for larger phase 2 registration trial
25 March 2024
Read more
Freemasons New Zealand renews support for CAR T-cell therapy
10 November 2023
Read more